ReviewTopics in antiviral medicine2024
CROI 2024: The Challenges of Sustained Viral Suppression, Advanced HIV Disease, and Ending the HIV Epidemic Targets.
Review in Topics in antiviral medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on the HIV care cascade demonstrated challenges in achieving Ending the HIV Epidemic (EHE) targets across all 18 EHE focus metropolitan areas, but innovative adherence interventions using point-of-care tenofovir testing and motivational interviewing support care cascade outcomes in Namibia and South Africa, respectively. Data on treatment with long-acting injectable (LAI) antiretroviral therapy (ART) demonstrated high acceptability, retention, and virologic suppression including in groups that were not well represented in clinical trials including persons born female and persons with detectable viral loads. The adjuvanted hepatitis B vaccine appeared to be safe and appeared to be superior to conventional hepatitis B vaccines in persons with HIV (PWH) who were prior nonresponders to the hepatitis B vaccine. New therapies are in the pipeline for LAI hepatitis C medication that may cure hepatitis C with 1 injection. ACTG (AIDS Clinical Trials Group) A5359 showed that long-acting cabotegravir/rilpivirine (LA CAB/RPV) can be used effectively in PWH experiencing adherence challenges to oral ART and suggested a paradigm for treating this population with an unmet medical need. Studies on resistance mutations in SARS COV-2 show that treatmentrelated emergent resistance does not appear to contribute to viral rebound or have the potential for transmitted drug resistance. The data presented on HIV and maternal and pediatric health included findings from studies on the implementation of first-line dolutegravir-based ART in pregnant and postpartum women and children, along with results of a phase I/II trial involving LA CAB/RPV in adolescents. Additionally, various abstracts addressed hypertensive disorders in HIV during pregnancy and postpartum periods, as well as the intersection of HIV and mental health in women and youth.
Indexed as
Identifiers
39746674PMC11361756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.